Application of Gannetespib compound in preparation of medicine for resisting human adenovirus type 7

Through the application of Ganetespib compounds, the problem of lack of specific drugs for human adenovirus type 7 infection has been solved, and efficiently inhibited viral replication and progeny virus yields have been achieved, which significantly improved the survival rate of infected cells and has broad clinical application prospects.

CN119055642AInactive Publication Date: 2024-12-03HUBEI UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410992174.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure CN119055642A_ABST
    Figure CN119055642A_ABST
Patent Text Reader

Abstract

The invention discloses application of Gannetespib in preparation of a medicine for resisting human adenovirus type 7, and belongs to the technical field of antiviral medicines. An anti-ADV7 activity research experiment of the Gannetespib shows that the compound Gannetespib inhibits the cytopathic effect (CPE) generated by ADV7 on a host cell Hela, enhances the cell survival rate and reduces the progeny virus yield, and has the potential to be applied to preparation of anti-ADV7 virus drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antiviral drugs, and in particular to the use of a Ganetespib compound in the preparation of an anti-human adenovirus type 7 drug. Background Art

[0002] Human adenovirus type 7 (ADV7) is a widely distributed non-enveloped double-stranded DNA virus with a diameter of 90-100nm. The capsid is dihedral and its replication does not depend on the division of host cells. Human adenovirus (ADV) infection is very common and can cause various diseases in the human body, mainly respiratory tract infections. There are three main types of adenoviruses associated with respiratory diseases, namely ADV-3, ADV-5 and ADV-7. It is known that adenoviruses have a low risk of causing serious diseases. Commonly, it can cause acute respiratory fever, but it has a great impact on children. In severe cases, it can cause pneumonia in children. ADV7 has been confirmed to be an important cause of pneumonia in children. ADV7 can cause severe or fatal respiratory tract infections in children under 7 years old, and it is easy to cause outbreaks and endanger the health of infants and young children. At present, there is a lack of drugs with strong specificity and few side effects for ADV7 infection in clinical practice. At present, symptomatic treatment is mainly adopted. Therefore, it is imperative to develop specific drugs against ADV-7 infection.

[0003] Ganetespib (STA-9090) is a HSP90 inhibitor with IC values ​​of 100 in 8 OSA cell lines. 50 STA-9090 is an active metabolite of STA-1474, currently in Phase III clinical trials. STA-9090 can effectively block cell proliferation and induce apoptosis in a wide range of human tumor cell lines at low nanomolar concentrations, and also has effects on many receptor tyrosine kinase inhibitors and tanespimycin-resistant cell lines. STA-9090 exhibits effective cytotoxicity in a range of solid and hematological tumor cell lines, including those expressing mutant kinases that are resistant to small molecule tyrosine kinase inhibitors. Administration of STA-9090 resulted in significant reduction of tumors in mice in several tumor xenograft models, and appeared to be less toxic. In addition, STA-9090 has better tumor penetration than tanespimycin. In malignant mast cell and OSA xenograft models, STA-9090 inhibited tumor growth in vivo. However, there are few reports on the use of STA-9090 for antiviral therapy.

[0004] The present invention evaluated the inhibitory activity of STA-9090 against ADV7 virus. Summary of the invention

[0005] The purpose of the present invention is to provide a method for preparing a drug for resisting human adenovirus type 7 virus by using Ganetespib compound in view of the above situation.

[0006] The Ganetespib (C 20 H 20 The chemical structure of the compound N4O3 is shown below: .

[0007] As a preferred embodiment, the inhibition rate of the Ganetespib compound on ADV7 is 97% at 12.5 µM.

[0008] Furthermore, the drug refers to a Ganetespib compound added with pharmaceutically acceptable excipients and carriers to prepare an anti-ADV7 virus preparation.

[0009] Furthermore, the preparation is any one of granules, tablets, pills, capsules, injections or dispersions.

[0010] The advantages and beneficial effects of the present invention are as follows: The purpose of the present invention is achieved by testing the activity of Ganetespib by a standard virus activity test method. Through a large number of biological experiments, the present invention found that the Ganetespib compound has anti-ADV7 virus activity. Specifically, it can inhibit the cytopathic effect caused by the ADV7 virus, enhance the survival rate of infected cells, inhibit the replication and proliferation of the ADV7 virus in cells, and reduce the yield of progeny viruses. This shows that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 It is the effect of STA-9090 on the survival rate of Hela cells infected with ADV7 virus.

[0012] Figure 2 It is the inhibitory effect of STA-9090 on Hela cell CPE caused by ADV7 virus.

[0013] Figure 3 It is the inhibitory effect of STA-9090 on the production of ADV7 progeny virus. DETAILED DESCRIPTION

[0014] The Ganetespib compound (STA-9090) used in the present invention was purchased from a reagent company.

[0015] The present invention relates to the use of a Ganetespib compound (STA-9090) in the preparation of an anti-ADV7 virus drug.

[0016] The drug refers to Ganetespib compound (STA-9090) added with pharmaceutically acceptable excipients and carriers for preparing an anti-ADV7 virus preparation.

[0017] The preparation is granules, tablets, pills, capsules, injections or dispersions.

[0018] The Ganetespib compound (STA-9090) of the present invention has the following chemical structural formula: .

[0019] Example 1 The application of STA-9090 in the present invention as an anti-ADV7 virus found that STA-9090 has a significant anti-ADV7 virus effect, which indicates that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects.

[0020] The present invention conducted an anti-ADV7 virus activity research experiment on the above compounds, and the experimental results are as follows: In the following, unless otherwise specified, the materials and operating methods used in the present invention are well known in the art.

[0021] 1. Test content: Analysis of the anti-ADV7 viral activity of Ganetespib compound: The present invention combines cytopathic effect analysis and MTT cell viability assay to evaluate the anti-ADV7 viral activity of STA-9090.

[0022] 2. Test methods: 2.1.1 Toxicity of compounds to host Hela cells Hela cells were plated on 96-well plates and cultured in a 37°C, 5% CO2 incubator until the cells grew to a full monolayer. The cell culture medium was discarded and cell maintenance medium containing different concentrations of the test compound was added to continue culturing. After 48 hours, the cytotoxicity was observed under a microscope and recorded. The cell survival rate was determined by the MTT method. SPSS 11.5 software was used to calculate the median cytotoxic concentration (CC) of the drug for cells. 50 ). Cell survival rate = (mean OD of drug group 492 Value / average OD of cell control group 492 value) × 100%.

[0023] 2.1.2 Inhibitory activity of compounds against ADV7 Hela cells were plated on 96-well plates and cultured in a 37°C, 5% CO2 incubator until the monolayer was full. The culture medium was discarded and 100 TCID 50 The cells were infected with ADV7 virus solution for 1.5 hours, and different concentrations of test compounds (ribavirin as a positive control drug) were added to incubate the cells. After continuing to culture for about 48 hours, when about 90% CPE lesions appeared in the virus control wells, the cytopathic effect (CPE) was observed under a microscope. The observation and recording method of CPE: no cytopathic effect is recorded as -, 25% or less cytopathic effect is recorded as +, 25%-50% cytopathic effect is recorded as ++, 50%-75% cytopathic effect is recorded as +++, and 75% or more cytopathic effect is recorded as +++.

[0024] After CPE observation, the MTT method was used to detect the inhibition rate of drugs on ADV7. The specific steps were as follows: 50 μL (5 mg mL MTT) was added to each well. -1 ), incubate for 3-4 h, remove the supernatant, add an equal volume of DMSO to dissolve the precipitate. Read the corresponding absorbance (OD) at 492 nm using an enzyme reader. 492 The inhibition rate of the drug on ADV7 was calculated using the following formula. The half effective concentration (EC) of the drug was calculated using SPSS 11.5 software. 50 ).

[0025]

[0026] 2.1.3 Therapeutic Index (TI) of Drugs TI = CC 50 / EC 50 The higher the therapeutic index, the greater the antiviral potential.

[0027] 3. Experimental results Table 1 Cytotoxicity and anti-ADV7 activity of STA-9090

[0028] The results of the compound cytotoxicity and anti-ADV7 activity tests are shown in Table 1. The concentration-dependent effects of the compounds on the viability of Hela cells treated with STA-9090 are shown in Table 1. Figure 1 It was found that the maximum inhibition rate of STA-9090 was about 97% at 12.5 µM.

[0029] Example 2 The present invention has conducted an in-depth study on the anti-ADV7 virus activity of STA-9090, and implemented a test on the inhibitory effect of STA-9090 on the yield of ADV7 progeny viruses. The test results are as follows: 1. Test content The inhibitory effect of STA-9090 on the production of ADV7 progeny viruses was detected after ADV7 virus infected Hela cells.

[0030] 2. Test methods Hela cells in the logarithmic growth phase were plated in 24-well plates. After the cells were confluent with a monolayer, 100 TCID50 ADV7 was used to infect the cells. After incubation at 37°C for 1.5 h, the virus solution was removed, the cells were washed three times with PBS, and a cell maintenance solution containing 6.25 µM was added. After 48 h, the cells and supernatant culture medium were collected, and the ADV7 virus titer was determined by the TCID50 method after three freeze-thaw cycles at -20°C and 37°C.

[0031] 3. Test results like Figure 2 As shown, the cell survival rate of Hela cells infected with ADV7 treated with STA-9090 was significantly increased compared with the virus control group, indicating that the compound can significantly inhibit the activity of ADV7.

[0032] like Figure 3 As shown, the virus titer of Hela cells treated with STA-9090 was significantly decreased compared with the virus control group, which was decreased by 6.9 log compared with the virus control.

[0033] In summary, STA-9090 has a strong inhibitory effect on ADV7 virus activity, can inhibit Hela cell death caused by ADV7 virus, and can be prepared into a clinically effective drug against ADV7 virus infection.

[0034] It should be understood that the above embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.

Claims

1. The use of Ganetespib compound in the preparation of anti-ADV7 virus drugs, characterized in that: The chemical structure of the Ganetespib compound having anti-ADV7 virus activity is shown below: 。 2. The use of the Ganetespib compound according to claim 1 in the preparation of anti-ADV7 virus drugs, characterized in that: The Ganetespib compound has an inhibition rate of 97% against ADV7 virus at 12.5 µM.

3. The use of the Ganetespib compound according to claim 1 in the preparation of anti-ADV7 virus drugs, characterized in that: The drug refers to a Ganetespib compound added with pharmaceutically acceptable excipients and carriers to prepare an anti-ADV7 virus preparation.

4. The use of the Ganetespib compound according to claim 1 in the preparation of anti-ADV7 virus drugs, characterized in that: The preparation is any one of granules, tablets, pills, capsules, injections or dispersants.

Citation Information

Patent Citations

  • Susceptibility to hsp90-inhibitors

    CN102216775A

  • Application of Gannetespib in preparation of medicine for resisting adenovirus infection

    CN114917222A

  • Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)

    US20110305634A1

  • Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors

    US20170275375A1